摘要
目的探讨人表皮生长因子受体-2(HER-2)、血管内皮生长因子(VEGF)和Ki67在乳腺癌组织中的表达及其与临床病理因素的关系。方法采用免疫组化法检测49例乳腺癌患者组织中HER-2、VEGF和Ki67的表达。结果 HER-2、VEGF和Ki67在乳腺癌组织中的阳性表达率分别为36.7%、69.4%、79.6%;HER-2在乳腺癌组织学分级和淋巴结转移中的表达差异有统计学意义(P<0.05);VEGF在乳腺癌淋巴结转移中的表达有显著差异(P<0.05);Ki67表达在乳腺癌组织学分级中的差异有统计学意义(P<0.05)。结论 HER-2、VEGF和Ki67与乳腺癌的发生、发展密切相关,联合检测可作为判定乳腺癌预后的评估指标。
Objective To explore the expression of human epidemic growth factor receptor- 2 （HER-2）, vascular endothelial growth factor （VEGF） and Ki67 in the tissue of breast cancer and its relationship with clinical pathological factors. Methods Expressions of HER-2, VEGF and Ki67 in 49 cases of female breast cancer were detected by immunohistochemistry. Results The positive rates of expressions of HER-2, VEGF and Ki67 were 36.7%, 69.4% and 79.6%. The expression of HER - 2 in breast cancer was significantly different in grading and lymph node metastasis （ P 〈 0.05）. The expression of VEGF was significantly different in lymph node metastasis （ P 〈 0.05 ）. The expression of Ki67 in different grade in tumor tissue was statistically significant （P 〈 0.05 ）. Conclusion HER-2, VEGF and Ki67 are closely related with the development of female breast cancer, and combined detection can be used as an evaluation index for judging the prognosis of breast cancer.
出处
《实用临床医药杂志》
CAS
2015年第15期38-40,共3页
Journal of Clinical Medicine in Practice
